CD209

Across TCGA pan-cancer cohorts, CD209 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated CD209 data layer compared with 9 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher CD209 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CD209 expression acts as an unfavorable survival marker, although some lineages such as CHOL and LUAD show a favorable association.

UVM, CHOL, and LUAD are the cancer types where CD209 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	OS	Median	All	0.354	0.785	<.001	78	view →
CHOL	DFS	Median	All	0.674	0.126	<.001	39	view →
LUAD	DFS	Quartile	All	0.459	0.226	.001	38	view →
SCLC	OS	Tertile	IV	0.137	0.548	.004	36	view →
HNSC	DFS	Median	III,IV	0.664	0.514	.006	29	view →
LUSC	DFS	Median	II,III,IV	0.589	0.880	.002	26	view →
SKCM	OS	Quartile	All	0.420	0.247	.004	23	view →
LGG	DFS	Tertile	All	0.851	0.672	.002	18	view →
READ	DFS	Quartile	III,IV	1.000	0.703	.012	16	view →
KIRP	DFS	Tertile	II,III,IV	0.169	0.751	.026	15	view →
THCA	DFS	Tertile	IV	0.946	0.636	.018	12	view →
LIHC	OS	Median	All	0.464	0.654	.022	5	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

CD209–UVM (OS)

Open the UVM breakdown →